Anteris Technologies Ltd. is a structural heart company that designs, develops, and commercializes innovative medical devices for treating heart valve diseases. Its flagship product, the DurAVR Transcatheter Heart Valve system, features a single-piece, native-shaped biomimetic design engineered to mimic the performance of a healthy aortic valve, addressing aortic stenosis through minimally invasive procedures. The system incorporates ADAPT anti-calcification tissue, which transforms xenograft material into durable bioscaffolds resembling human tissue, and the ComASUR delivery system, a balloon-expandable mechanism with a reinforced steerable catheter for precise navigation through heart anatomy. Anteris Technologies Ltd. operates across key markets including the United States, Germany, Australia, Switzerland, and Sweden, with a focus on advancing cardiac care via science-driven innovations. Headquartered in Toowong, Australia, the company partners with interventional cardiologists and cardiac surgeons to deliver paradigm-shifting hemodynamic performance and deliverability in transcatheter aortic valve replacement therapies.